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Abstract
Background: The proteasome is a validated anti-cancer target and various small-molecule inhibitors are currently in
clinical development or on the market. However, adverse events and resistance associated with those proteasome
inhibitors indicate the need for a new generation of drugs. Therefore, we focused on developing an oral proteasome
inhibitor with improved efficacy and safety profiles.
Method: The in vitro inhibition of the 20S proteasome catalytic activities was determined in human multiple myeloma
(MM) cellular lysates with fluorogenic peptide substrates specific for each catalytic subunit. Cell cytotoxicity was assessed
with the ATP bioluminescence assay using human cell samples from tumor cell lines, MM patients or normal healthy
donors. In mice bearing human MM xenografts, a single dose of LC53-0110 was administered orally, and concentration-
time profiles of LC53-0110 and the 20S proteasome catalytic activities in plasma, blood, and tumor were determined.
The efficacy of repeat-dose compound with regard to tumor growth inhibition in vivo was also evaluated in the same
MM xenograft models.
Results: LC53-0110 is far more specific for the chymotrypsin-like proteolytic (β5) site of the 20S proteasome as compared
to bortezomib, carfilzomib, or ixazomib. LC53-0110 treatment showed accumulation of ubiquitinated proteins, inhibited
cell viability with a low nM range potency in various tumor cell lines, and showed potent activity on CD138+ cells isolated
from MM patients who are resistant/refractory to current FDA-approved drug treatment. When a single dose was
administered orally to tumor-bearing mice, LC53-0110 showed both greater maximum and sustained tumor
proteasome inhibition as compared with ixazomib in MM xenograft models. The robust pharmacodynamic responses
in tumor correlated with tumor growth regression. In addition, LC53-0151, an analog of LC53-0110, in combination
with pomalidomide, a third-generation immunomodulatory drug, showed synergistic inhibition of tumor growth both
in vitro and in the xenograft mouse model.
Conclusions: In view of the in vitro, in vivo, and ex vivo profiles, further investigation of additional LC compounds in
preclinical studies is warranted for the nomination of a clinical development candidate.
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Background
The 26S proteasome is a multimeric complex consisting of
a centrally-located 20S core catalytic complex flanked by
19S regulatory subunits [1–3]. The 19S caps contain mul-
tiple ATPase active sites and ubiquitin binding sites which
recognize and unfold ubiquitinated protein substrates and
transfer them to the 20S core. The 20S complex contains
two outer α rings and two inner β rings. Each β ring
contains three active enzymatic sites with distinct substrate
specificities: chymotrypsin-like (CT-L) on the β5 subunit,
trypsin-like (T-L) on the β2 subunit, and caspase-like (C-L)
on the β1 subunit. The proteasome plays a critical role in
cellular homeostasis by degrading a variety of proteins in-
volved in cell cycle control, signal transduction, apoptosis,
antigen processing, cell differentiation and proliferation
through the ubiquitin-proteasome pathway. Therefore, the
sites of the 26S proteasome, both 19S and 20S subunits,
have been drug targets for various disease indications
including cancer [4].
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Bortezomib, a drug administered intravenously or sub-
cutaneously, was the first proteasome inhibitor targeting
enzymatic sites of the β chain and validated the prote-
asome as an anti-cancer target [5, 6]. It was approved
for the treatment of mantle cell lymphoma and MM.
Since FDA-approval of bortezomib, second-generation
proteasome inhibitors with improved therapeutic indices
have been pursued in various systems ranging from
virtual modeling to tumor-bearing animals [7, 8]. Re-
cently, carfilzomib also administered intravenously, was
approved for the treatment of refractory MM [9–11].
There are currently other various small-molecule inhibi-
tors in clinical development including ixazomib [12],
oprozomib [13], and marizomib [14]. Whereas ixazomib
and oprozomib are orally bioavailable proteasome inhibi-
tors, marizomib is an intravenously administered inhibi-
tor with less protease specificity.
Here, we describe the characterization of the preclinical
pharmacology of LC53-0110 and its analog which are
novel, reversible, selective, potent, and orally bioavailable
proteasome inhibitors. We investigated the effects of LC-
53-0110 on proteasome CT-L activities in vitro and in
tumor cell lines, and addressed the anti-cancer mechan-
ism by analyzing apoptosis pathways. Furthermore, we
validated its effects on primary human myeloma cells
of multiple myeloma patients. Finally, the compound’s
in vivo effects were evaluated in multiple myeloma
xenograft mouse models.
Methods
Human tumor cell lines and chemicals
Cell lines were obtained from the American Type Culture
Collection (ATCC) and maintained in culture conditions
at 37 °C under 5 % CO2. RPMI8226, MM.1S, U2932, Su-
DHL-8, H1650, NCI-H1975, MDA-MB-231, and MCF-7
cells were maintained in RPMI-1640 (Gibco) containing
10 % fetal bovine serum (FBS, heat-inactivated; Gibco)
and 1 % penicillin-streptomycin-amphotericin B (Gibco).
HCT116 and HT-29 cells were maintained in McCoy’s 5A
medium (Gibco) containing 10 % FBS and 1 % penicillin-
streptomycin-amphotericin B.
Bortezomib, ixazomib, and carfilzomib were synthesized
in our laboratory and the structures were confirmed by
nuclear magnetic resonance. Pomalidomide was purchased
from Tokyo Chemical Industry. Fluorogenic peptide
substrates Suc-Leu-Leu-Val-Tyr-AMC (7-amido-4-me-
thyl-coumarin) for the proteasomal CT-L activity, Z-
Ala-Arg-Arg-AMC for the proteasomal T-L activity,
and Z-Leu-Leu-Glu-AMC for the proteasomal C-L activ-
ity were purchased from Calbiochem, EMD Millipore.
In vitro enzyme assays
RPMI8226 cell lysate was used for the in vitro prote-
asome inhibition assay. Cells were washed with PBS and
resuspended in 20 mM Tris–HCl, pH 7.5. Then, cells
were lysed on ice by dounce homogenization and the
supernatants were collected by centrifugation. The assay
was conducted in 96-well plates by incubating 2 μg of
lysates with serial dilutions of a test compound and
20 μM of substrate at 37 °C for 1 h. After incubation,
production of hydrolyzed AMC groups was measured
using a FlexStation II Fluorometer (Molecular Devices)
or using a Spectra MAX Gemini Fluorometer (Molecu-
lar Devices) with an excitation filter of 380 nm and an
emission filter of 460 nm.
The non-proteasome protease panel assay was con-
ducted at 10 μM of a test compound using standard
substrate-based assays (GenScript, NJ). After 10 min in-
cubation of proteases and inhibitor compounds at room
temperature, substrates for respective proteases were
added to initiate the reactions, and products from each
reaction were analyzed with PHERAstar Plus (BMG
LABTECH) or FlexStation 3 (Molecular Devices) using
kinetics or endpoint model. Percent inhibition was calcu-
lated as [1- (sample activity-substrate control)/(enzyme
activity-substrate control)]×100. The positive control of
each non-proteasome protease showed 96–103 % inhib-
ition, thereby validating the assay performance.
Cell viability assays
Cell cytotoxicity was assessed using the ATP Biolumin-
escence Assay. RPMI8226, MM.1S, U2932, Su-DHL-8
cells were plated onto 96-well microtiter plates in cul-
ture medium and then treated with a serial dilution of
compound in medium containing a final concentration
of 0.5 % DMSO. Cultures were incubated for 48 h and
cells were then assayed for viability using the CellTiter-
Glo Luminescent Cell Viability Assay kit (Promega). For
the adherent cell lines, cells were plated and incubated for
24 h. Cells were then treated with a serial dilution of com-
pound for an additional 72 h and assayed for viability.
For the MTT [3-(4,5-dimethythiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide] assay, MM.1S cells were plated
and incubated with DMSO or varying concentrations of
LC53-0151 and pomalidomide. At the end of the incuba-
tion, the water soluble MTT was added and cell viability
was determined by measuring optical density at 560 nm
using SpectraMax M5e (Molecular Devices).
Western immunoblot analysis
RPMI8226 cells were seeded and treated with either 500
nM of test compounds or 0.1 % DMSO. After incubation
for 1 h, cells were washed with media three times, and
incubated for an additional 4 or 24 h. Cells were washed
with ice-cold PBS and lysed with Pro-Prep lysis buffer
(iNtRON Biotechnology). Protein lysates were analyzed
by Western immunoblotting using the following anti-
bodies: anti-Ubiquitin (Enzo Life Sciences), anti-Hsp70
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and anti-Hsp27 (Abcam), anti-Gadd34 (Proteintech), anti-
caspase-8 (BD pharmingen), anti-β-Catenin, anti-p21,
anti-phospho Hsp27 (S82), anti-caspase-9, anti-PARP, and
anti-α-Tubulin (Cell Signaling). Images were obtained
using ChemiDoc MP (Bio-Rad) and quantitation was done
using Image Lab Software (Bio-Rad).
Human primary cell samples
All human cell samples from MM patients and normal
healthy donors were obtained after approval by the Insti-
tutional Review Board (IRB) for Human Research at the
Catholic University of Korea and independent Ethics
Review Board at the LG Life Sciences with written in-
formed consent, respectively.
Primary MM cells were retrieved from bone marrow of
patients and were enriched by Ficoll density centrifugation
to a purity of >90 %, as necessary. Purity was assessed by
cytomorphology on stained samples. CD138+ cells were
collected using magnetic beads (Miltenyi Biotec) and
plated at a density of 8 × 104 cells per well onto 96-well
plates in RPMI-1640 (WELGENE) containing 10 % FBS
(WELGENE), 1 % penicillin-streptomycin-amphotericin B
(Gibco), and 2 mM L-glutamine. Cells were then treated
with a serial dilution of compound in medium containing
a final concentration of 0.2 % DMSO. Cultures were incu-
bated for 48 h and cells were then assayed for viability
using the CellTiter-Glo Luminescent Cell Viability Assay
kit (Promega).
Peripheral blood mononuclear cells (PBMCs) isolated
from the heparinized blood samples of normal healthy
donors were also plated and processed as described above.
Tumor-bearing mouse studies
In vivo efficacy studies were performed in female BALB/
c nude mice (8 weeks old) purchased from ORIENT Bio
or female NOD.SCID mice (11–13 weeks old) purchased
from HFK Bioscience. The animals were housed and
maintained in a controlled environment including a 12 h
light and 12 h dark cycle with automatic timers and re-
ceived food and water ad libitum. All experiments were
done under protocols approved by the Institutional
Animal Care and Use Committee (IACUC). Moribund
animals were sacrificed when necessary and animal car-
casses were disposed of according to IACUC guidelines.
1 × 107 MM.1S tumor cells in 0.1 ml of Dulbecco’s
Phosphate-Buffered Saline (1:1 matrigel) were implanted
subcutaneously into the right flank of female athymic
nude mice. Tumor growth was monitored with calipers
and mice were divided into homogeneous cohorts ac-
cording to their initial tumor volume. Then within each
cohort, mice were randomized to treatment groups just
before dose initiation, thus ensuring that all the groups
have comparable baselines. The compounds were formu-
lated in 0.5 % methyl cellulose and administered at the
indicated doses and regimens by oral gavage at a dose vol-
ume of 10 mL/kg. For the RPMI8226 model, a total of 1 ×
107 cells in 0.2 ml of PBS (1:1 matrigel) were implanted
subcutaneously into the hind flank of female NOD.SCID
mice. Whole blood was collected by cardiac puncture into
tubes containing sodium heparin and cells were harvested
by centrifugation. Blood cell pellets and tumor tissues
were homogenized in lysis buffer (50 mM Tris–HCl,
pH 8.0, 5 mM EDTA, 150 mM NaCl, 0.5 % Nonidet P-40,
0.5 mM phenylmethylsulfonyl fluoride, and 0.5 mM di-
thiothreitol) for 30 min at 4 °C. The lysates were centri-
fuged at 14,000 × g for 30 min, and the supernatants were
collected as whole blood cell extracts and tumor cell ex-
tracts, respectively, for pharmacodynamic analysis. Blood,
plasma, and tumor tissue samples were extracted with
acetonitrile (0.1 % formic acid) containing internal stand-
ard, followed by centrifugation at 3600 rpm for 10 min.
Supernatant was injected into the LC-MS/MS system for
pharmacokinetic analysis. The mean, standard deviation
(SD), and standard error of the mean (SEM) were calcu-
lated for each experimental group, and statistical analyses
were performed using standard two tailed Student’s t-test
(significance defined as P ≤ 0.05).
Results
LC53-0110 is a selective inhibitor of CT-L activity
LC53-0110 was identified following optimization of a
new scaffold identified in silico for in vitro inhibition of
proteasome CT-L activities using the fluorogenic sub-
strate succinyl-Leu-Leu-Val-Tyr-AMC and human MM
RPMI8226 cell lysates. LC53-0110 displayed potent in-
hibitory activity against CT-L, with IC50 values in the
single nM range (Table 1). LC53-0110 was less potent
against the other proteolytic sites of the 20S proteasome,
i.e., T-L and C-L, with IC50 values of >20,000 nM and
600–1300 nM, respectively. When the relative potency
of LC53-0110 was compared side by side with other pro-
teasome inhibitors, LC53-0110 was found to be more
specific toward CT-L inhibitory activity. LC53-0110 was
Table 1 Inhibition of the proteasome
Compound (route
of administration)
Proteasome inhibition, IC50 (nM) Binding
kineticsCT-L, β5 T-L, β2 C-L, β1
Bortezomib (IV/SC) 2 ~ 4 2400 ~ 3700 16 ~ 29 reversible
Carfilzomib (IV) 7 ~ 9 400 ~ 460 420 ~ 590 irreversible
Ixazomib (PO) 3 ~ 5 >10000 6 ~ 7 reversible
LC53-0110 (PO) 1 ~ 5 >20000 600 ~ 1300 reversible
The in vitro inhibition of the 20S proteasome catalytic activities was determined
in RPMI8226 cellular lysates with fluorogenic peptide substrates specific for each
catalytic subunit. Three reference compounds were tested in the assays along
with LC53-0110. Binding kinetics was determined by assessing CT-L activity in
RPMI8226 cells at different time points after 1-h pulse treatment of cells with
a compound.
CT-L chymotrypsin-like, T-L trypsin-like, C-L caspase-like. IV intravenous, SC
subcutaneous, PO per os, by mouth
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determined to be a reversible inhibitor when CT-L activ-
ity was assessed in vitro at different time-points after
RPMI8226 cells were pulse-treated for 1 h with the com-
pound (data not shown). When assessed against repre-
sentative non-proteasomal proteases (Fig. 1), LC53-0110
had relatively weak or no inhibitory activities except
against neutrophil Elastase (serine protease with P1 spe-
cificity of valine), for which it showed 65 % inhibition at
10 μM, a potency similar to that of bortezomib and ixa-
zomib. It is noteworthy that LC53-0110 differentiated
itself from those proteasome inhibitors by showing no
inhibitory activity against Cathepsin G (serine protease
with P1 specificity of phenylalanine/leucine/tyrosine).
LC53-0110 inhibits viability in human tumor cell lines
When effects on cell viability were determined by bio-
luminescent measurement of cellular ATP, LC53-0110
inhibited viability in RPMI8226 cells with IC50 values of
6–12 nM at 48 h (Table 2). In additional tumor cell lines
with diverse origins and genetic backgrounds, LC53-
0110 was found to inhibit viability with IC50 values ran-
ging from 3 nM to 25 nM, demonstrating potency in
both hematologic and solid tumor cell lines tested.
For the assessment of the compound’s effect on the
proteasome-dependent protein degradation pathway,
cell lysates were prepared from RPMI8226 four hours
after a one-hour pulse treatment with a compound and
assessed by Western blot analysis with an ubiquitin-
specific monoclonal antibody. The level of ubiquiti-
nated proteins with a group of slower migrating bands
in cells treated with LC53-0110 or its analog LC53-0151
were increased as compared to DMSO-treated cells
(Fig. 2a), confirming inhibition of proteasome protease
activities in cells, thereby blocking the proteasome-
dependent polyubiquitinated protein degradation pathway.
The inhibition of proteasome function was also confirmed
by accumulation of the direct proteasome substrates p21
and β-Catenin (Fig. 2b).
Fig. 1 Inhibition of non-proteasomal proteases. 10 μM of proteasome
inhibitor compounds were tested with a panel of proteases, Cathepsin
G (serine protease with P1 specificity of phenylalanine/leucine/tyrosine),
Elastase (neutrophil serine protease with P1 specificity of valine),
Cathepsin B (cysteine protease), Renin (aspartate protease), and
ACE (metalloprotease angiotensin converting enzyme). Percent
inhibition was calculated based on compound’s effect on protease
activity subtracted with a substrate control without an enzyme
Table 2 Inhibition of cellular viability
Cell line Tumor type IC50 (nM)
RPMI8226 Multiple myeloma 6 ~ 12
MM.1S Multiple myeloma 3 ~ 6
U2932 Activated B-cell like diffuse large B-cell lymphoma 6 ~ 9
SU-DHL-8 Diffuse large B-cell lymphoma 11 ~ 18
HCT116 Colorectal carcinoma 13 ~ 14
HT-29 Colorectal adenocarcinoma 11 ~ 16
H1650 Lung carcinoma 7 ~ 22
NCI-H1975 Lung carcinoma 2 ~ 14
MDA-MB-231 Breast adenocarcinoma 8 ~ 14
MCF-7 Breast adenocarcinoma 14 ~ 25
The cytotoxic effects of LC53-0110 on a panel of tumor cell lines were determined
by bioluminescent measurement of cellular ATP using CellTiter-Glo reagent.
Hematologic and solid tumor cells were incubated with the compound for 48 h or
72 h, respectively prior to assay
Fig. 2 Accumulation of ubiquitinated proteins and activation of
apoptosis in cells. Lysates were prepared from RPMI8226 cells 4 h (a)
or 24 h (b, c, d) after a 1-h treatment with 0.1 % DMSO or 500 nM
of proteasome inhibitors. Western blot analysis was done with anti-
Ubiquitin, anti-p21, anti-β-Catenin, anti-Hsp70, anti-phospho Hsp27
(S82), anti-Hsp27, anti-Gadd34, anti-caspase-8, and anti-caspase-9
antibodies. α-Tubulin was used as a loading control. Cleaved
caspase-8 and 9 bands on the western blot were quantitated and
expressed as a fold-increase over DMSO control
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Since accumulation of excessive or misfolded proteins
triggers the cellular stress response including upregula-
tion of heat shock protein (Hsp) expression and the
unfolded protein response (UPR) [15–17], some of these
components were examined to assess the mechanism of
action of LC53-0110 and its analog LC53-0151. In
RPMI8226 cells, significant basal levels of Hsp70, Hsp27,
and phospho-Hsp27 were detected (Fig. 2c). Upon treat-
ment with either compound, levels of Hsp70 and Hsp27
were increased, suggesting a collective cellular protec-
tion response by molecular chaperones. Phosphorylation
of Ser82, one of the main phosphorylation sites of
Hsp27 in vivo by MAP kinase-activated protein kinase 2
(MAPKAPK2) [18], was also increased, likely affecting
its chaperone activity [19]. GADD34 was greatly in-
duced upon compound treatment, suggesting UPR-
dependent ER stress-induced cell death [15]. Therefore,
to further address the mechanism of compound effects
on cell viability, two types of caspases were assessed for
activation of the apoptotic cell death pathway (Fig. 2d,
Additional file 1: Figure S1A). Whereas caspase-8 trig-
gers the apoptotic signal transduction cascade upon
binding of death receptor ligands to their correspond-
ing receptors, caspase-9 links induction of stress signaling
pathways to the mitochondrial death pathway [20, 21].
Since activation of these caspases is associated with the
cleavage of their inactive pro-enzyme forms, the level
of cleaved caspases were determined in RPMI8226 cells.
LC53-0110 and its analog LC53-0151 increased cleaved
caspase-8 levels four to seven-fold and caspase-9 levels
two to four-fold, respectively. Therefore, both com-
pounds triggered mitochondria-dependent and -inde-
pendent apoptotic cell death signaling pathways, thus
leading to cleavage of the apoptotic marker poly(ADP-ri-
bose) polymerase (PARP) (Additional file 1: Figure S1B).
Treatment of human multiple myeloma MM.1S cells with
either LC53-0110 or LC53-0151 also showed similar re-
sults (data not shown).
LC53-0110 inhibits viability in primary human myeloma
cells
To assess effects of LC53-0110 on viability of primary
human myeloma cells, CD138+ cells were purified
from bone marrow samples of MM patients who had
been either newly diagnosed or exposed to various
standard therapies (Table 3). When effects on cell via-
bility were determined by bioluminescent measure-
ment of cellular ATP, the median IC50 for LC53-0110
and a range value were 15 nM and 32 nM, respectively
(Fig. 3b, Additional file 2: Figure S2). In patient 4 and
patient 14 samples where IC50s could not be deter-
mined due to ambiguous slopes, viability at 12.5 nM
was 15 and 10 %, respectively (Fig. 3a). Therefore,
regardless of prior therapy regimens applied to the
patients and whether or not the patients became resist-
ant or refractory, LC53-0110 showed a potent inhib-
ition of viability in primary myeloma cells from the
patients. The reference compound ixazomib was less
potent than LC53-0110 in those patient samples
(Fig. 3a). When normal PBMC samples from healthy
donors were assessed for cytotoxicity, LC53-0110 and
ixazomib showed more than 50 % viability at 10,000
nM, the highest concentration tested (data not shown).
Therefore, normal PBMC cell viability was relatively
less affected by proteasome inhibitors as compared
with that of myeloma cells.
Table 3 Summary of multiple myeloma patients
Patient Age Type D-S stage VR TR LR Number of
treatment linesa
11 >65 IgG-λ IIIa N.A. N.A. N.A. naive
4 >65 IgG-κ IIIa N.A. N.A. N.A. naive
8 <65 λ IIIa Y N.A. Y 4
15 >65 IgA-λ IIIa Y N.A. Y 2
3 <65 IgG-λ IIIa Y Y Y 4
16 >65 IgG-κ IIIa Y Y Y 6
14 <65 λ IIIb Y Y Y 3
6 <65 IgG-κ IIIa Y N N.A. 2
7 <65 λ IIIb N Y Y 3
D-S Stage: The Durie-Salmon staging system. V: bortezomib. T: thalidomide. L:
lenalidomide. R: resistance or refractory. N.A.: Not Applicable. Type: paraproteins
IgG or IgA, κ-light chains κ or λ-light chains λ
aFor patients who received autologous stem cell transplantation (ASCT), a
regimen of induction + ASCT+/−maintanence was counted as one treatment
line. Naive: no past treatment
Fig. 3 Inhibition of cellular viability in patient-derived samples. a CD138+
cells were purified from the bone marrow samples of MM patients (3, 4,
6–8, 11, 14–16). The cytotoxic effects of LC53-0110 (filled rectangle)
and ixazomib (open circle) were determined by bioluminescent
measurement of cellular ATP using CellTiter-Glo reagent after 48 h
of treatment. Results are expressed as % cell viability over DMSO
control. b The IC50 values for LC53-0110 treated MM patients
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LC53-0110 strongly inhibits proteasome catalytic activity
in tumor xenograft models
Having established anti-viability in tumor cell lines,
systemic effects of LC53-0110 on tumor growth in an
organism were assessed. MM.1S xenograft tumors
were subcutaneously implanted in the hind flank of
athymic nude mice and the ability of LC53-0110 to
inhibit endogenous proteasomal CT-L activity was
examined following a single oral dose of 50 mg/kg.
The tumors were harvested 1, 7, 24, 48 or 72 h after
treatment and homogenized in lysis buffer. Blood was
collected at the same time as tumor tissues were har-
vested, and blood lysates were prepared as well. The
inhibition of proteasomal CT-L catalytic activity in the
tumors was 82 % at 1 h, reached a maximum of 97 %
at 48 h, and persisted through 72 h (Fig. 4a). In con-
trast, the inhibition of CT-L catalytic activity in the
blood decreased from 72 % at 1 h to 29 % at 7 h, and
further decreased with only minimal or no inhibition
evident by 72 h.
The concentrations of LC53-0110 in plasma, blood,
and tumors were also determined in this study (Fig. 4b).
Tumor concentrations were 1 μM at 1 h and decreased
to 0.4 μM at 7 h and 24 h. Then, the compound levels
gradually decreased to 0.1 μM by 72 h. In contrast,
blood concentrations were 1.8 μM at 1 h and continu-
ously decreased to 0.03 μM by 72 h. The slope of con-
centration change in plasma over time was similar to
that in blood with 3.3 μM at 1 h and 0.04 μM by 72 h.
Therefore, whereas 97 % inhibition of tumor CT-L activ-
ity occurred at the tumor concentration of 0.2 μM, 14 %
inhibition of blood CT-L activity occurred at the blood
concentration of 0.16 μM. The data presented here show
the pharmacodynamic effect of LC53-0110 to be greater
in tumors over blood as well to outlast a detectable
plasma or blood exposure.
LC53-0110 displays robust anti-tumor activity in tumor
xenograft models
The efficacy of repeat-dose LC53-0110 with regard to
tumor growth inhibition in vivo was evaluated in the pre-
viously described MM.1S as well as RPMI8226 xenograft
models. Due to its durable target modulation activity, i.e.,
a sustained pattern of proteasomal CT-L inhibition in
tumors, it could be predicted that dosing every several
days or even once a week with LC53-0110 might result in
significant anti-tumor efficacy in vivo. Indeed, when ad-
ministered orally at 50 mg/kg of LC53-0110 (Fig. 5a),
MM.1S tumor regression was observed on day 4 post-
dosing (42–52 % of start tumor volume) and almost
complete tumor regression was achieved by day 15 with
all dosing regimens tested (twice or once a week sched-
ules). In contrast, when orally administered twice a week
at 5 mg/kg, ixazomib showed a maximum tumor regres-
sion on day 8 (36 % of start tumor volume), after which
the tumors appeared to regrow, reaching 58 % of start
tumor volume and 72 % tumor growth inhibition on day
15 as compared to the vehicle control group.
The strong efficacy of LC53-0110 was also evident in
the RPMI8226 xenograft model. Dose-dependent tumor
growth inhibition was achieved by LC53-0110 at 25 mg/
kg (56 %) and 50 mg/kg (82 %) on day 22 when orally
administered twice a week (Fig. 5b). Tumor growth in-
hibition by LC53-0110 dosed 50 mg/kg once a week was
similar to that seen with the twice a week dosing regi-
men throughout the treatment period. Moreover, tumor
growth inhibition by 50 mg/kg LC53-0110 administered
orally was greater than 0.6 mg/kg bortezomib or 2.0 mg/kg
carfilzomib, both of which were administered intraven-
ously. The anti-tumor effect of LC53-0110 as assayed by
tumor volume change was also confirmed by weight meas-
urement of tumors extracted after final tumor volume
measurement in tumor-bearing mice (data not shown).
Fig. 4 PD and PK profiles of LC53-0110 in mice bearing human multiple myeloma xenografts. a MM.1S tumor bearing mice were administered orally
with a single dose of LC53-0110 at 50 mg/kg, and the 20S proteasome catalytic activities in tumor and blood were evaluated with CT-L subunit-specific
fluorogenic peptide substrates. Data points, mean +/−SE (n= 3). b In the same study, concentration-time profiles of LC53-0110 in plasma, blood, and
tumor were determined. Data points, mean +/−SD (n= 3)
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An analog of LC53-0110 synergizes with an
immunomodulatory drug for anti-tumor activity
To address if an LC compound enhances anti-tumor activ-
ity when combined with immunomodulatory drugs,
MM.1S cells were treated with pomalidomide, a third-
generation immunomodulatory drug, for 24 h and then
with the LC53-0110 analog LC53-0151 for an additional
24 h across a range of concentrations. When cell prolifera-
tion was measured by MTT analysis, cells treated with
LC53-0151 or pomalidomide as a single agent showed
lower viability as compared to DMSO-treated control cells,
and the combination of both agents showed a greater in-
hibition of viability than either agent alone (Fig. 6a). More-
over, isobologram analysis confirmed that LC53-0151 and
pomalidomide induced synergistic cytotoxicity in MM.1S
cells (combination index analyzed by CalcuSyn S/W< 1.0).
In order to address if the observed synergism is also
displayed in vivo, the efficacy of oral repeat-dose LC53-
0151 was evaluated with regard to tumor growth inhib-
ition in MM.1S xenografted nude mice with or without
pomalidomide treatment. LC53-0151 and pomalidomide
were orally administered for 3 weeks at 20 mg/kg twice
a week and at 2.5 mg/kg for 5 days per week, respect-
ively. Whereas pomalidomide treatment displayed 10 %
reduction of tumor volume with no statistically signifi-
cance as compared to vehicle-treated mice, LC53-0151
treatment exhibited 43 % reduction of tumor volume
(Fig. 6b). In addition to its anti-tumor efficacy as a mono-
therapy, LC53-0151 potentiated the anti-tumor efficacy of
pomalidomide, resulting in a 63 % reduction of tumor
volume on day 22 as compared to vehicle-treated mice.
The improved efficacy of LC53-0151 when combined with
pomalidomide was also confirmed by weight measure-
ment of tumors extracted after final tumor volume meas-
urement in tumor-bearing mice (Fig. 6c).
Discussion
Since bortezomib came on the market, there has been sig-
nificant improvement in survival of MM patients [6].
However, the drug has some drawbacks such as toxicities
including gastrointestinal symptoms (e.g., diarrhea), fa-
tigue, thrombocytopenia, anemia, and peripheral neur-
opathy (PN), which is a common complication [22, 23]. In
addition, it must be administered by intravenous or sub-
cutaneous injection. Carfilzomib, another proteasome in-
hibitor on the market, has a low incidence of PN, but it
has common serious adverse events (AEs) including fever,
pneumonia, acute renal failure, and congestive heart fail-
ure, and it also must be administered by intravenous injec-
tion [24–27]. Since proteasome inhibitors emerged as an
important component of MM treatment, logistical chal-
lenges for those injection approaches have become clear,
especially for patients who need long-term therapy. Re-
cent studies of the investigational oral proteasome inhibi-
tor ixazomib, an improved version of bortezomib, showed
a lower incidence of grade 3 PN as compared to bortezo-
mib, and drug-related other grade 3 AEs including diar-
rhea, fatigue, thrombocytopenia, neutropenia, and skin
rash [28–33]. With improving survival in MM, the oral
route of administration of ixazomib is considered to be
high value, especially with the all-oral triple combination
of ixazomib, an immunomodulatory agent, and a steroid
being the most convenient and effective [34]. This is a par-
ticularly important factor for post-transplant maintenance,
which can last several years. Therefore, we focused on
developing an oral proteasome inhibitor that can be differ-
entiated from ixazomib on the efficacy and safety profiles.
LC53-0110 is a more specific inhibitor of CT-L as
compared to ixazomib, which has a similar potency
toward C-L as CT-L (Table 1). The biological role of the
Fig. 5 Anti-tumor activity of LC53-0110 in mice bearing human multiple
myeloma xenografts. a The LC and reference compounds were orally
administered twice a week (BIW) or once a week (QW) in mice bearing
MM.1S xenografts as indicated. The mean tumor volume for each
animal in the vehicle and treatment groups was determined during
the study. Data points, mean+/−SE (n = 6). b LC53-0110 was orally
administered twice a week or once a week in mice bearing RPMI8226
xenografts as indicated, and reference compounds were intravenously
administered twice a week. The mean tumor volume for each animal
in the vehicle and treatment groups was determined during the study.
Data points, mean+/−SE (n = 8)
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individual proteasomal active sites is not fully understood.
No phenotypic or proteolytic defects were observed upon
inactivation of C-L sites by site-directed mutagenesis of
catalytic threonines in the yeast S. cerevisiae [35, 36].
Using chemical inhibitors or activity-based probes of C-L
site, there have been some efforts to address the question
of whether inhibition of this site is important for anti-
tumor activity, especially in conjunction with inhibition of
CT-L site [37–40]. However, due to the properties of the
selective compounds including potency, cell permeability,
stability, ADME/PK, and toxicity, the physiological conse-
quences of C-L inhibition still need to be established. The
study with carfilzomib, a relatively specific CT-L inhibitor
like LC53-0110, supported the notion that inhibition of
cellular CT-L activity is sufficient to kill hematological
tumor cells, in particular MM cells, with minimal effects
on normal leukocytes [41]. This is consistent with the
findings in our study with LC53-0110, i.e., accumulation
of ubiquitinated proteins, decrease of cell viability, and
increase of apoptosis in MM cells (Table 2, Fig. 2).
LC53-0110 with CT-L specificity also showed potent in-
hibition of viability of MM cells obtained from patients in
a dose-dependent manner (Fig. 3). Although it is risky to
make a conclusion with a limited number of patients,
patients who were newly diagnosed (patients 11 and 4)
showed the lower end of cellular potency (i.e., most
potent) as compared to those patients with multiple prior
therapies (2–6 regimens) including proteasome inhibitors,
thalidomide, lenalidomide, dexamethasone, histone deace-
tylase inhibitor, and chemotherapeutic drugs. Interest-
ingly, LC53-0110 showed increased potency in MM cells
obtained from bortezomib- and ixazomib-refractory
patient with 10 % viability at 12.5 nM, at which ixazomib
did not show any effect on viability (patient 14, Fig. 3a).
LC53-0110 clearly showed the ability to inhibit viability of
MM cells of patients who were progressed after various
treatments, with potency similar to those of MM cell lines.
Therefore, it is likely that the proteasome CT-L active
sites inhibited by LC53-0110 were not affected in these
patients.
In human MM xenograft models in nude mice, oral
administration of LC53-0110 showed much greater pro-
teasome inhibition in tumor compared with blood,
which was also the case for ixazomib [42] (Fig. 4a; and
data not shown). However, LC53-0110 showed greater
maximum and sustained tumor proteasome inhibition as
compared with ixazomib (>90 % with a duration of action
of at least 72 h). On repeat dosing, LC53-0110 showed
complete tumor growth regression in MM.1S xenografts,
a greater effect as compared with ixazomib (Fig. 5a). The
Fig. 6 Anti-tumor activity of an LC53-0110 analog combined with an immunomodulatory drug. a The cytotoxic effects of 5 nM of LC53-0151 or
2 μM of pomalidomide alone or together on MM.1S cells were determined by MTT assay. b LC53-0151 or pomalidomide alone or together in mice bearing
MM.1S xenografts as indicated. The mean tumor volume for each animal in the vehicle and treatment groups was determined during the study. c The
mean tumor weight for each animal in the vehicle and treatment groups was determined at the end of the study. Data points, mean+/−SE (n= 8)
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efficacious activity of LC53-0110 was also demonstrated
by the lack of measurable tumor mass even six weeks after
the final dose in the surviving mice (data not shown).
LC53-0110 also showed greater tumor growth inhibition
than bortezomib and carfilzomib in RPMI8226 xenografts
at well-tolerated doses (Fig. 5b). However, in this efficacy
model, all 8 mice died or were euthanized due to mori-
bund condition the day after the first oral treatment with
ixazomib at 5 mg/kg, which most likely is related to the
possible toxicity of ixazomib.
Various agents have been proven to enhance anti-
tumor activity in combination with other agents, and the
addition of immunomodulatory drugs such as thalido-
mide or lenalidomide is considered one of the standard
MM therapies [43–48]. Recently, treatment of relapsed
MM with the proteasome inhibitor carfilzomib in combin-
ation with lenalidomide and dexamethasone showed
better progression-free survival and overall response than
lenalidomide and dexamethasone alone [49]. Pomalido-
mide is a new generation of immunomodulatory drug
which was shown to confer a survival advantage even in
patients who are refractory to both bortezomib and lenali-
domide [50]. Pomalidomide is currently being investigated
in combination with dexamethasone [51, 52], with borte-
zomib and dexamethasone [53], or with carfilzomib and
dexamethasone [54] in patients with relapsed/refractory
MM. LC53-0151, an analog of LC53-0110, in combination
with pomalidomide also showed further synergistic inhib-
ition of tumor growth both in vitro and in the xenograft
mouse model (Fig. 6).
Conclusions
The orally available LC53-0110 and its analog LC53-
0151 having strong efficacy and toxicity profiles may fur-
ther improve the therapeutic efficacy, safety, and con-
venience for patients when used in combination with
orally available immunomodulatory drugs. Therefore, in
view of the in vitro, in vivo, and ex vivo profiles, further
investigation of additional LC compounds in preclinical
studies is warranted for the nomination of a clinical de-
velopment candidate.
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